在正治疗期间治疗粘膜:紧急呼吁采取预防策略
1Basic Sciences, Biomedical Stomatology Research Group, Universidad de Antioquia U de A, Medellín 050010, Colombia. martin.ardila@udea.edu.co.
World journal of clinical cases
|October 28, 2024
概括
粘膜在正牙患者中很常见,会影响舒适性和服从性. 积极的管理和患者教育是减少这些病变的关键在正义牙科治疗期间.
科学领域:
- 牙科 牙科 牙科 牙科
- 口腔医学是指口腔医学.
背景情况:
- 粘膜经常发生在正治疗期间.
- 这些病变会对患者的舒适性和治疗坚持产生负面影响.
研究的目的:
- 审查 ортодонтических患者的粘膜的患病率,原因和管理.
- 强调主动策略来缓解这些口腔病变.
主要方法:
- 最近研究的文献综述.
- 临床观察的分析.
主要成果:
- 粘膜是正治疗中的一个重要并发症.
- 积极的措施和患者教育可以减少的发生率和严重程度.
结论:
- 一个多学科的方法对于管理与正相关的粘膜是必不可少的.
- 临床实践的调整确保了患者的安全与不断发展的正牙技术.
相关概念视频
Peptic Ulcer Disease IV: Management
74
Medical treatment strategies for peptic ulcers encompass various methods. The primary goal of treatment is to diminish gastric acidity and strengthen mucosal defense mechanisms.
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
74
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents
362
The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
362
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents
397
In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
397
Tonsillitis II: Management
103
This lesson will focus on the different treatment options for managing tonsillitis, which typically depend on the cause and severity.
103
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors
356
Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI) tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
356
Peptic Ulcer Disease V: Surgical Management and Nursing Care
233
Surgical management and nursing care are crucial in treating Peptic Ulcer Disease (PUD). Here is an organized and enhanced overview of the surgical interventions and the associated nursing care for PUD:
Surgical Interventions for Peptic Ulcer Disease
Surgical Interventions for Peptic Ulcer Disease
233


